Investigational drug · Phase 3
Amrubicin
Also called: Japan only
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
25
Any phase or sponsor naming "Amrubicin"
First trial start
2023
May 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Amrubicin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Small Cell Lung Cancer (SCLC)
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Amrubicin" as an intervention, largest first.
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT06801834 · 695 participants (planned) · Start Apr 4, 2025 · Primary completion Oct 2029
Drug: Sacituzumab Govitecan (SG); Topotecan and 2 more · For: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sites: Anchorage, Alaska; Hot Springs, Arkansas; Anaheim, California · 219 sites in all
- AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line ChemotherapyPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT00547651 · 637 participants · Start Sep 1, 2007 · Primary completion May 1, 2011
Drug: Amrubicin; Topotecan · For: Small Cell Lung Cancer
Sites: Muscle Shoals, Alabama; Tucson, Arizona; Little Rock, Arkansas · 140 sites in all
- Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02481830 · 569 participants · Start Sep 14, 2015 · Primary completion Aug 17, 2018
Drug: Nivolumab; Topotecan and 1 more · For: Lung Cancer
Sites: Little Rock, Arkansas; New Haven, Connecticut; Atlanta, Georgia · 151 sites in all
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06203210 · 540 participants (planned) · Start May 21, 2024 · Primary completion Jan 30, 2028
Drug: Ifinatamab deruxtecan; Topotecan and 2 more · For: Small Cell Lung Cancer
Sites: Springdale, Arkansas; Fullerton, California; Los Angeles, California · 229 sites in all
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07365241 · 531 participants (planned) · Start Jul 2, 2026 · Primary completion Sep 2030
Drug: ABBV-706; Topotecan and 3 more · For: Small Cell Lung Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Goodyear, Arizona · 72 sites in all
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT05740566 · 509 participants · Start May 31, 2023 · Primary completion Jan 29, 2025
Drug: Tarlatamab; Lurbinectedin and 2 more · For: Small Cell Lung Cancer (SCLC)
Sites: Mobile, Alabama; Anchorage, Alaska; Little Rock, Arkansas · 223 sites in all
- A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)Pivotal-lookingRecruiting
Zai Lab (Shanghai) Co., Ltd.Industry
NCT07218146 · 480 participants (planned) · Start Nov 30, 2025 · Primary completion Jun 30, 2028
Drug: ZL-1310; Investigator's Choice of Therapy · For: Small-cell Lung Cancer
Sites: La Jolla, California; Sacramento, California; Aurora, Colorado · 165 sites in all
- Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung CancerPivotal-lookingCompleted
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Industry
NCT00660504 · 300 participants · Start Apr 2008 · Primary completion Feb 2012
Drug: Amrubicin Hydrochloride; Etoposide-Cisplatin combined chemotherapy · For: Lung Cancer
Sites: Fuzhou, China; Lanzhou, China; Guangzhou, China · 15 sites in all
- Amrubicin (AMR) Trial in Patients With Non-small Cell Lung CancerPivotal-lookingCompleted
Sumitomo Pharma Co., Ltd.Industry
NCT01207011 · 202 participants · Start Oct 2010 · Primary completion Jun 2014
Drug: Amrubicin hydrocloride; Docetaxel · For: Lung Cancer
Sites: Multiple Locations, Japan
- Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)Pivotal-lookingTerminated
Sumitomo Pharma Co., Ltd.Industry
NCT00286169 · 130 participants (planned) · Start Apr 2006
Drug: Amrubicin Hydrochloride · For: Small-cell Lung Cancer
Sites: Chugoku, Japan; Chūbu, Japan; Hokkaido, Japan · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- BCG vaccination in Korea, Japan, and Taiwan: Current status and future perspectives.
Choe YJ, Kim KJ, Yoshida LM, et al. · Hum Vaccin Immunother 2026
- Multifocal primary hepatic small cell neuroendocrine carcinoma treated with sequential systemic therapies.
Inada H, Tanaka K, Yoshinari M, et al. · Clin J Gastroenterol 2026
- Primary adrenal small cell neuroendocrine carcinoma in a patient with sarcoidosis and synchronous colon adenocarcinoma.
Sano A, Takeichi T, Miyamaoto A, et al. · JCEM Case Rep 2026
- Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.
Kurata T, Sugawara S, Akamatsu H, et al. · Int J Clin Oncol 2026
- Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.
Rudin CM, Ahn MJ, Schuler M, et al. · Ann Oncol 2026
- Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan.
Yamaguchi S, Nakatani E, Asada R · Ther Innov Regul Sci 2026
Also in development for Small Cell Lung Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.